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DNA nanotechnology has taken a giant 
leap toward real-life applications during 
the recent years.[1,2] After the invention 
of DNA origami in 2006,[3] the whole 
research field has grown exponentially.[2,4] 
Today there are numerous ways to build 
discrete user-defined, accurate, and fully 
addressable DNA nanostructures, such as 
scaffolded 2D and 3D origami[3,5,6] with 
twists, curves, and bends,[7,8] Lego-like 
objects formed from molecular canvases,[9] 
and wireframe-based meshed construc-
tions.[10–12] The computational tools[11–13] 
for designing such objects have emerged 
along with these techniques, and this pro-
gress has opened up new possibilities for 
the researchers to effortlessly build their 
own nanostructures for tailored uses.[14] 
Recently demonstrated applications 
based on customized DNA nanostruc-
tures include artificial ion channels,[15] 
optical (plasmonic and photonic) struc-
tures,[16,17] high-precision molecular posi-
tioning devices,[18] modifiable templates for 
arranging, e.g., proteins,[19–21] polymers,[22] 
and nanotubes,[23] as well as DNA-assisted 
techniques for creating arbitrarily shaped 
metal nanoparticles.[24–26]
Fully addressable DNA nanostructures, especially DNA origami, pos-
sess huge potential to serve as inherently biocompatible and versatile 
molecular platforms. However, their use as delivery vehicles in therapeu-
tics is compromised by their low stability and poor transfection rates. This 
study shows that DNA origami can be coated by precisely defined one-
to-one protein-dendron conjugates to tackle the aforementioned issues. 
The dendron part of the conjugate serves as a cationic binding domain 
that attaches to the negatively charged DNA origami surface via electro-
static interactions. The protein is attached to dendron through cysteine-
maleimide bond, making the modular approach highly versatile. This 
work demonstrates the coating using two different proteins: bovine serum 
albumin (BSA) and class II hydrophobin (HFBI). The results reveal that 
BSA-coating significantly improves the origami stability against endonu-
cleases (DNase I) and enhances the transfection into human embryonic 
kidney (HEK293) cells. Importantly, it is observed that BSA-coating attenu-
ates the activation of immune response in mouse primary splenocytes. 
Serum albumin is the most abundant protein in the blood with a long 
circulation half-life and has already found clinically approved applications 
in drug delivery. It is therefore envisioned that the proposed system can 
open up further opportunities to tune the properties of DNA nanostruc-
tures in biological environment, and enable their use in various delivery 
applications.
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In addition to these applications, an increasing effort has 
been put into applying DNA nanostructures as smart drug-
delivery vehicles and biomolecular devices at the cellular 
level.[27–30] These examples cover logic-gated nanorobots for 
modulating cell signaling,[31] structures for delivering anti-
cancer drugs[32–34] and for circumventing drug-resistance,[35,36] 
as well as carriers equipped with siRNA molecules,[37] CpG-
triggers,[38] and functional enzymes.[39] Despite this progress, it 
has been observed that the transfection of DNA structures is 
generally low[40] and that these objects are prone to degradation 
in biological environment.[41] Nevertheless, there exist tech-
niques to presumably enhance both stability and transfection 
rates of the DNA structures by utilizing different sophisticated 
protection and coating mechanisms, such as virus protein[42] 
or lipid membrane encapsulation.[43] It has also been shown 
that spermidine-stabilized structures could be efficiently trans-
fected by electroporation.[44] Moreover, it has been suggested 
that the delivery rates could be improved by employing DNA 
intercalators,[45] by directly incorporating specific proteins into 
the structures,[46] or by using cationic polymer coating.[47–49] For 
DNA binding and coating purposes, dendrons and dendrimers 
are ideal polymer structures.[50,51] They are regularly branched 
synthetic molecules with essentially monodisperse structure[52] 
and high density of functional groups capable of binding var-
ious biomolecules with high affinity through multivalent and 
multimodal interactions.[53] Thus, they provide access to syn-
thetic macromolecules with a primary structure of the same 
level of precision as DNA origami, proteins, or other biological 
molecules.[54]
Biohybrid structures that further combine synthetic poly-
mers with biological macromolecules can bring together 
the best features of both material types—the versatility of 
synthetic materials and highly specific biological proper-
ties. Synthetic polymers attached on a protein surface can, 
for example, provide augmented or entirely new features 
to the unique biological property of the protein. Examples 
of such enhancements include improved pharmacokinetic 
properties,[55] stimuli-responsive properties (e.g., modulation of 
enzyme activity, selective purification by phase separation, and 
size-dependent binding),[56] formation of higher-order struc-
tures,[57] and biosensing and binding to new targets.[58]
Here, we present a straightforward and versatile method to 
protect DNA origami nanostructures by coating them with pro-
tein coronas. The method is solely based on electrostatic interac-
tions between protein–dendron conjugates and a DNA origami 
(Figure 1), and, therefore, it provides an attractive alternative to 
the other protection techniques[43] and protein coatings[46] that 
are based on the modifications of the individual DNA strands 
in the complex structure or hydrophobic interactions.[59]
We demonstrate the feasibility of the conjugation by 
anchoring two different proteins to the dendron via a cysteine–
maleimide bond: bovine serum albumin (BSA; Figure 1A, B) 
and class II hydrophobin (HFBI). As a reference we also used 
three facially different Janus dendrimers. All structures are 
shown in Figure S1 in the Supporting Information. The mul-
tivalent dendron part of the conjugate acts as a (cationic) syn-
thetic DNA binding domain that attaches to negatively charged 
60-helix bundle (60 HB, dimensions of 20 nm × 20 nm × 
33 nm) DNA origami surface (Figure 1C). 60HB serves here 
as a model structure and has the dimensions of a regular hex-
agonal or square lattice 3D origami prepared with the M13 scaf-
fold. By adjusting the concentration ratio of conjugates versus 
origami, it is possible to achieve a complete and dense protein 
shield for the origami structures (Figure 1D). In this work, we 
observed that especially BSA coating of the origami gives prom-
ising results, as the transfection rates can be enhanced 2.5-fold 
compared to bare origami. Remarkably, the coating also pro-
vides full protection against DNase I endonuclease, whereas 
under the same experimental conditions the plain origami 
gets completely degraded (Figure 1D). The binding efficiency 
was examined using gel electrophoretic mobility shift assay 
(EMSA) and transmission electron microscopy (TEM). As the 
potential use DNA origami nanostructures for therapeutic pur-
poses require intravital administration, we wished to ascertain 
Adv. Healthcare Mater. 2017, 6, 1700692
Figure 1. Schematics of the protein–dendron coating of DNA origami nanostructures. A) Bovine serum albumin (BSA) is anchored to the second-
generation dendron (G2) via a cysteine–maleimide bond. B) The structure of the whole BSA-G2 conjugate. C) BSA-G2 can be attached to a brick-like 
DNA origami (60-helix bundle, 60HB) via electrostatic binding: a positively charged domain of BSA-G2 binds to a negatively charged surface of the 
DNA origami. D) BSA-G2 coating of DNA origami provides protection against endonucleases, attenuates immune activation, and enhances cellular 
delivery rates of the nanostructures.
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the immunocompatibility of our nanostructures. Appropriately, 
the BSA-based coating of the structures was shown to attenuate 
immune activation of the mouse primary splenocytes (Inter-
leukin 6 (IL-6) assay), similarly as recently demonstrated for 
albumin-coated virus particles (Figure 1D).[60] In addition, we 
tested if the combination of reference Janus dendrimers could 
form a bilayer coating over DNA origami (results are shown in 
the Supporting Information).
60-helix bundles were prepared as described previously[61] 
and the excess staple strands were removed by poly(ethylene 
glycol)-based purification[62] (see also the Supporting Informa-
tion for details). The purified 60HBs (constant concentration 
of 4.4 × 10−9 m) were mixed with increasing concentrations 
of protein–dendron conjugates (synthesized as previously 
reported[63,64]) in an aqueous solution. Two different dendron 
generations were used: generation 1 (G1) contains nine proto-
natable amines (HFBI-G1 and BSA-G1) and the second genera-
tion (G2) includes 27 amines that can be protonated (HFBI-G2 
and BSA-G2). The unique structural property of these protein–
polymer conjugates is their precisely defined, one-to-one struc-
ture where the conjugation site (one free cysteine) is exactly 
known. Therefore, such conjugates minimize dispersity issues 
and can provide clear structure–property relationships.
The results were analyzed using gel EMSA, as shown in 
Figure 2A. The conjugate concentration/origami concentration 
ratio (cC/cO) was varied between 0–3000 for HFBI dendrons 
and 0–2000 for BSA dendrons. As can be seen in Figure 2, G1 
dendrons did not show any binding within the studied concen-
tration range. However, EMSA with G2 dendrons clearly reveals 
interactions between the conjugates and the origami. HFBI-G2 
and 60HBs tend to aggregate at high concentrations (cC/cO = 
1000–3000) as the leading band gets dimmer, but the band in 
front of the well becomes more intense (the leading band com-
pletely disappears at cC/cO = 3000). In the case of BSA-G2, the 
band is clearly shifting at cC/cO = 1000 and 2000, indicating a 
proper binding without undesired aggregation.
TEM analysis (Figure 2B–D) confirms the EMSA result: 
60HBs and BSA-G2 conjugates form discrete objects, 
whereas HFBI-G2 forms large aggregates (see the Supporting 
Information). The larger size and inert nature of BSA helps to 
prevent dendron-mediated cross-linking (also avoiding hydro-
phobic interactions in the case of HFBI) and consequently 
yields origami structures coated with a single protein layer. It 
can be readily observed that the bare origami (Figure 2B) and 
the BSA-coated origami (Figure 2C) have distinct morphologies, 
and the quantitative analysis of the dimensions of the objects 
(Figure 2D) further proves the dense and relatively uniform 
protein coating. The measured dimensions of 60HB (thickness 
of 19.4 ± 1.8 nm and length of 33.4 ± 2.1 nm) precisely cor-
respond to the designed dimensions (thickness of 20 nm and 
length of 33 nm), whereas dimensions of the BSA-G2-coated 
60HB are extended on average by 12 nm compared to the plain 
60HB (thickness of 31.1 ± 5.1 nm and length of 45.7 ± 6.5 nm). 
This observation implies that the origami structures are coated 
with a dense shield of proteins (BSA-G2 dimensions ≈7 nm × 
6 nm × 6 nm).
After the protein–dendron coating was verified and opti-
mized, the transfection properties of the complexes were 
examined in vitro. For that, the origami structures were 
labeled with AlexaFluor 488 dye (six dyes per origami) and 
transfected to human embryonic kidney cells (HEK293) with 
and without the protein coating (see the Supporting Informa-
tion). Transfection was studied using two different origami 
concentrations (0.64 × 10−9 m and 1.28 × 10−9 m), and for 
coating, both HFBI-G2 and BSA-G2 were added at a ratio of 
cC/cO = 2000. The cells were incubated for 12 h with the sam-
ples, after which their viability was verified, and the fixed cells 
(nuclear staining with 4′,6-diamidino-2-phenylindole (DAPI) 
Adv. Healthcare Mater. 2017, 6, 1700692
Figure 2. Gel EMSA and TEM micrographs of the samples. A) Agarose gel EMSA of a constant amount of DNA origami (cO = origami concentra-
tion = 4.4 × 10−9 m) complexed with increasing amounts of HFBI-G1, HFBI-G2, BSA-G1, and BSA-G2 conjugates (cC/cO = conjugate concentration/
origami concentration). EMSA indicates low binding efficiency of both G1 conjugates, whereas HFBI-G2 induces aggregation of the complexes. 
However, EMSA reveals successful complexation of BSA-G2 and DNA origami as the origami bands clearly shift at concentrations cC/cO = 1000 and 
2000 (bottom panel). B,C) The BSA-G2 complexation is confirmed by TEM as the shape and the dimensions of the objects are changing. B) Plain 
60HB (negative staining) and C) BSA-G2-coated 60HB (cC/cO = 2000). The size of the insets is 80 nm × 80 nm. D) Analysis of the object dimensions 
(thickness and length) determined from the TEM images. The dimensions (curves show Gaussian fits) of the plain 60HB are shown in red and BSA-
G2-coated 60HB (cC/cO = 2000) in blue.
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was carried out after fixing) were imaged using confocal fluo-
rescence microscopy, as shown in Figure 3 (1.28 × 10−9 m data 
shown here, and 0.64 × 10−9 m data and HFBI-G2 coating are 
in the Supporting Information). The confocal micrographs 
show that the transfection efficiency for bare origami and 
HFBI-G2-coated origami is low (see Supporting Informa-
tion). However, with the BSA-G2 coating, the transfection 
is clearly improved (Figure 3A, right). In addition, it can be 
seen that in some cases BSA coating may enhance endosomal 
escape of the complexes as the lysosomes (LysoTracker, red) 
and the origami (AlexaFluor 488, green) are not co-localized 
(Figure 3B). However, uncoated and HFBI-coated 60HBs are 
not observed outside lysosomes in the same extent (see the 
Supporting Information). It is known that DNA nanostruc-
tures coated with proteins or other designer materials can be 
bound nonspecifically on cell surfaces and taken up via endo-
cytosis. Here, the BSA-G2-coated 60HB most probably follows 
the same pathway, which is promoted by the nonaggregated 
state and the discrete object size of the complex.
To further verify these results, the transfection efficiency was 
quantified using flow cytometry. The origami concentration in 
these experiments was adjusted to 0.32 × 10−9 m (cC/cO = 2000), 
and the results can be seen in Figure 3C. In general, the mean 
fluorescence intensity (that depicts the transfection efficiency) 
increases as the origami is coated with proteins. However, 
HFBI coating enhances the transfection only slightly, but by 
employing BSA coating, the transfection rate can be improved 
by a factor of 2.5 compared to bare origami. The observed dif-
ferences between BSA and HFBI can be related to the sample 
morphology, which in the case of HFBI coating is heavily aggre-
gated, lowering the transfection efficiency.
As the combination of BSA-G2 and the origami promisingly 
yields discrete and densely coated complexes with enhanced 
transfection properties, it is of high importance to study their 
structural integrity for the foreseen delivery applications. The 
potential protection of the protein coating was examined by 
exposing plain origami (cO = 3.3 × 10−9 m) and BSA-G2-coated 
structures (cO = 3.3 × 10−9 m, cC/cO = 2000) to DNase I diges-
tion (0–10 U in 20 µL sample volume) for 1 h at room tempera-
ture, after which their viability was verified by gel electropho-
resis. The intensities are obtained by integrating over the gel 
band, and the average value for the “0 U” sample is normal-
ized to 100 %. As can be seen from Figure 3D,E, the bare ori-
gami degrades almost completely as the nuclease concentration 
is increased. However, the BSA-coated structures retain their 
migration speed and band intensity throughout the concen-
tration range, which further indicates that the BSA coating is 
dense and that the coating efficiently protects the DNA struc-
ture from nuclease degradation. As a comparison, the Janus 
dendrimer-based coating resulted in less than 50% viability at 
the maximum concentration 10 U/20 µL (see the Supporting 
Information for details).
In this work we have used IL-6 secretion from splenic 
immune cells as readout for immune stimulation, as IL-6 is a 
proinflammatory cytokine produced by antigen presenting cells 
(APCs) in the acute phase of inflammation. Naked DNA mole-
cules are internalized by APCs and act as pathogen-associated 
molecular patterns, activating the immune system via TLR9, 
Adv. Healthcare Mater. 2017, 6, 1700692
Figure 3. A) Confocal micrographs of HEK293 cells after 12 h transfection with DNA origami. Left: 60HB, and right: BSA-G2-coated origami. The 
top panel (AlexaFluor 488, green) is the origami channel, the middle panel (LysoTracker, red) shows the lysosomes, and the bottom panel contains 
DAPI-stained nuclei and an overlay image of the top and the middle panel. B) Transfection of the BSA-G2-coated origami structures with bright field 
image of the cells. C) Quantification of the transfection efficiency (mean fluorescence intensity (F. I.)) by flow cytometry. The inset depicts cells only 
control sample. The data consist of the average values measured from two independent sample sets (data are expressed as mean ± data range, n ≥ 3). 
D) BSA-G2-based protection of DNA origami against endonuclease (DNase I). It shows the gel electrophoresis of 60HB (D, top) and 60HB coated by 
BSA-G2 (D, bottom) with increasing amount of added DNase I (identical for both gels). E) The normalized intensity of DNA origami bands calculated 
from three different gels (data are expressed as mean ± SD, n = 3). F) Production of IL-6 by mouse primary splenocytes. Cells were incubated with 
60HB and 60HB+BSA-G2 (0.08, 0.28, and 0.88 × 10−9 m) for 20 h (data are expressed as mean ± data range, n = 2). G) Splenocyte viability. Cells were 
treated for 20 h as in panel (C), followed by viability assay for 24 h (data are expressed as mean ± data range, n = 2).
© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1700692 (5 of 6)
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which leads to the production of proinflammatory cytokines. 
TLR9 signals via the NF-κB pathway, driving the expression of 
IL-6.[65] To assess the immune reactivity of the origami before 
and after coating, mouse primary splenocytes were harvested 
and treated immediately with increasing concentrations (0.08, 
0.28, and 0.88 × 10−9 m) of noncoated and coated 60HBs. 
Immune stimulation was assessed by measuring the produc-
tion of IL-6, with bacterial lipopolysaccharide (LPS) as a posi-
tive control. We observed a robust immune reaction from both 
LPS and uncoated origami, which was significantly attenuated 
by coating with BSA-G2 (Figure 3F). As evidenced by the TEM 
images, the BSA layer covering the origami is dense enough 
to mask the DNA core from detection by immune receptors. 
At the highest origami concentration, we observed over ten-
fold decrease in the IL-6 production. Importantly, cell viability 
was similar in all of the treatments, demonstrating that lack of 
immune activation is not due to cell death (Figure 3G). Taken 
together, we demonstrate excellent biocompatibility and escape 
from immune response as a result of DNA origami coating 
with BSA-G2.
As a conclusion, we have demonstrated an easily attain-
able method to improve the properties of DNA origami nano-
structures for the delivery applications. We have shown that 
the stability and the transfection rates of DNA origami can 
be enhanced by coating them electrostatically with protein–
dendron conjugates. Any protein that can be attached to the 
synthetic DNA-binding dendron via a cysteine–maleimide 
bond is suitable for the coating, but the electric charge of the 
protein should be taken into account in order to avoid unde-
sired aggregation. Here, we observed that especially the BSA 
coating protects the DNA origami from the nuclease degrada-
tion and improves the transfection to HEK cells. Furthermore, 
we showed that it is possible to “shield” the DNA nanocar-
riers from immune surveillance by complete serum albumin 
coating. As our approach is highly versatile, and therefore 
feasible for other proteins, we believe that the presented tech-
nique is a substantial addition to the ever-extending family of 
DNA-based delivery approaches[28–30] that serve as compelling 
alternatives to polymer, nanoparticle, and virus-based delivery 
methods.
Experimental Section
Materials for dendrimers and dendrons, details on DNA origami 
fabrication and purification, formation of protein–dendron–origami 
complexes, gel electrophoresis, DNase I assay, TEM and cryo-EM 
imaging, transfection and confocal imaging, flow cytometry, 
splenocyte IL-6 activation assay, viability assay, and additional TEM 
as well as confocal microscopy images are included in the Supporting 
Information.
All animal work was conducted in animal facilities of the University 
of Helsinki and approved by the National Animal Experiment Board of 
Finland.
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
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